Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon ‐α treatment in HBeAg‐positive chronic hepatitis B patients

This article is protected by copyright. All rights reserved
Source: Journal of Medical Virology - Category: Virology Authors: Tags: Research Article Source Type: research